Business Description
Captor Therapeutics SA
ISIN : PLCPTRT00014
Compare
Compare
Traded in other countries / regions
CTX.Poland60Q.Germany IPO Date
2021-04-19Description
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.04 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 4.11 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -98 | |||||
| 3-Year EPS without NRI Growth Rate | -57.4 | |||||
| 3-Year FCF Growth Rate | -260 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.58 | |||||
| 9-Day RSI | 59.55 | |||||
| 14-Day RSI | 56.96 | |||||
| 6-1 Month Momentum % | -35.74 | |||||
| 12-1 Month Momentum % | -60.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.32 | |||||
| Quick Ratio | 3.32 | |||||
| Cash Ratio | 2.83 | |||||
| Days Sales Outstanding | 79.28 | |||||
| Days Payable | 485.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.6 | |||||
| Shareholder Yield % | -10.19 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 52.28 | |||||
| Operating Margin % | -553.11 | |||||
| Net Margin % | -534.69 | |||||
| FCF Margin % | -418.22 | |||||
| ROE % | -102.2 | |||||
| ROA % | -76.17 | |||||
| ROIC % | -326.34 | |||||
| ROC (Joel Greenblatt) % | -802.29 | |||||
| ROCE % | -98.51 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 30.21 | |||||
| PB Ratio | 5.28 | |||||
| Price-to-Tangible-Book | 5.47 | |||||
| EV-to-EBIT | -4.26 | |||||
| EV-to-EBITDA | -4.62 | |||||
| EV-to-Revenue | 22.64 | |||||
| EV-to-FCF | -5.45 | |||||
| Price-to-Net-Current-Asset-Value | 6.12 | |||||
| Price-to-Net-Cash | 7.79 | |||||
| Earnings Yield (Greenblatt) % | -23.5 | |||||
| FCF Yield % | -14.9 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers